logo
Join Us

Interferon alfa-2a

  1. Drugs List
  2. Single Drug Name print
img

Interferon alfa-2a

It is medication used to treat hepatitis C and hepatitis B. More

Sharing is caring, show love and share the thread with your friends.

Description

It is medication used to treat hepatitis C and hepatitis B.

Generic Name

Interferon alfa-2a

Chemical names

NA

Brand names

Alferon, Inron-A, Intalfa, LG Intermax Alpha, Roferon-A, Zavinex

IUPAC name

NA

Pharmacokinetics

NA

Actions

NA

Dosage/Dosage form

NA

Therapeutic uses

This drug is used to treat hairy cell leukemia, chronic hepatitis C, AIDS-related Kaposi's sarcoma, and some types of CML (chronic myelogenous leukemia).

Adverse effects/Side effects

Marked increase in triglyceride levels, GI haemorrhage, severe infections, pulmonary infiltrates or pulmonary function impairment. Depressive illness, suicidal behaviour, irritability, insomnia, anxiety. Flu-like symptoms. Headache, dizziness, paraesthesia, confusion, impaired concentration, alteration in taste or smell. GI disturbances. Dryness of oropharynx, epistaxis, rhinitis, arrhythmia, sinusitis. Inj site reaction, alopecia, rash, dry skin or pruritus. Conjunctivitis, menstrual irregularity, visual disturbances. Coughing, dyspnoea. Myalgia, joint or bone pain, arthritis or polyarthritis. Bone marrow depression.

Interaction

  • Reduces clearance of theophylline.
  • Enhanced myelosuppression with other myelosuppressive drugs (e.g. zidovudine).
  • Drugs metabolised by CYP450 pathway (monitor for changes in pharmacologic or adverse effects of concomitant drug).
  •  Increased risk of toxicity of centrally acting drugs.
  • Increased risk of renal failure with interleukin-2.

Contraindications

Hypersensitivity. Autoimmune hepatitis, hepatic decompensation.

Storage

Store in a refrigerator at 2-8°C (36-46°F).

Information

Molecular weight

19241.1 Da

Molecular formula

C860H1353N227O255S9

CAS number

76543-88-9

Precautions

  • History of depression (monitor for signs).
  • Perform regular neuropsychiatric monitoring.
  • Perform ophthalmological exam on patients with preexisting ophthalmologic disorders (e.g. diabetic or hypertensive retinopathy).
  • Seizure disorders and/or compromised CNS function.
  • Preexisting or any history of cardiac disease.
  • Monitor CBC prior to and during therapy.
  • Concurrent use of myelosuppressive drugs or Myelosuppression.
  • Hypothyroidism, hyperthyroidism, DM.
  • Monitor patients with impaired renal function.
  • Creatinine clearance <50 ml/min.
  • May impair ability to drive or operate machinery.
  • Pregnancy and lactation.

Related News